UPDATE 1-US FDA releases latest list of safety issues

* List cites drugs by Merck, Pfizer, Genentech, others

* Agency in most cases says still evaluating drug
(Adds details from drug list)

WASHINGTON, Aug 27 (BestGrowthStock) – The U.S. Food and Drug
Administration has released its latest list of possible drug
safety concerns, citing Roche’s (ROG.VX: ) breast cancer drug
Herceptin and Sanofi Aventis’ (SASY.PA: ) heart drug Multaq,
among others.

The list, which comes out quarterly, covers safety issues
that the FDA flagged between April and June and was released on
the agency’s website on Friday.

Other drugs listed include Merck & Co Inc’s (MRK.N: ) birth
control Implanon, Pfizer’s (PFE.N: ) antibiotic Cleocin and
Novartis’ (NOVN.VX: ) Afinitor.

Takeda Pharmaceutical’s (4502.T: ) gout management drug
Uloric, AMAG Pharmaceutical’s (AMAG.O: ) anemia drug Feraheme and
Shire Plc’s (SHP.L: ) phosphate binder Fosrenol were also
included, among others.

In most cases, the FDA offered few clues into what the
concerns were and simply said the agency “is continuing to
evaluate this issue to determine the need for any regulatory
action.”

Merck’s cholesterol drug Zocor, Genentech’s HIV drug
Invirase and various GnRH agonists were also listed, but the
agency has already issued more specific safety alerts on those
drugs. Genentech is a unit of Roche.

Johnson & Johnson’s (JNJ.N: ) Nucynta, a pain treatment, was
also listed as having a risk of convulsions, hallucinations and
serotonin syndrome.

FDA also named omeprazole products, used to treat ulcers,
saying there is a risk the drug could cause low levels of
magnesium in the blood.

The drug manufacturers were not immediately available for
comment.

The list is online at: http://link.reuters.com/myg77n
(Reporting by Susan Heavey; Editing by John Wallace and
Richard Chang)

UPDATE 1-US FDA releases latest list of safety issues